Understanding the pathophysiology of paediatric heart failure and its treatment

Current Paediatrics

Volumn 16, Issue 6, 2006, Pages 398-405

  Simmonds, Jacob ^a   Franklin, Orla ^a   Burch, Michael ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

ACE inhibitors; B blockers; Diuretics; Heart failure; Paediatric; Pathophysiology; Physiology; Statins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; LOOP DIURETIC AGENT; METOLAZONE; NATRIURETIC PEPTIDE TYPE C; NESIRITIDE; SIMVASTATIN; SPIRONOLACTONE;

ADULTHOOD; ARTICLE; CHILDHOOD; CLINICAL IMMUNOLOGY; CLINICAL TRIAL; GROUPS BY AGE; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART OUTPUT; HORMONAL REGULATION; HUMAN; NEUROENDOCRINOLOGY; NEWBORN PERIOD; PATHOPHYSIOLOGY; PEDIATRIC CARDIOLOGY; PEDIATRICIAN; PHYSIOLOGY; PROFESSIONAL KNOWLEDGE; TREATMENT INDICATION;

EID: 33750055774     PISSN: 09575839     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cupe.2006.08.004     Document Type: Article

References (64)

1. Guyton AC, Hall JE. Contraction of skeletal muscle. In: Guyton AC, Hall JE, editors. Textbook of medical physiology, 10th ed. 2000. p. 67-86.
2. Guyton AC, Hall JE. Heart muscle; the heart as a pump. In: Guyton AC, Hall JE, editors. Textbook of medical physiology, 10th ed. 2000. p. 96-106.
3. Frank O. Zur Dynamik des herzmuskels. Z Biol 32 (1885) 370-447
4. Starling E.H., and Visscher M.B. The regulation of the energy output of the heart. J Physiol 62 (1926) 243-261
5. Opie LH. Mechanisms of cardiac contraction and relaxation. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine, 5th ed. 1997. p. 360-93.
6. Backx P.H., and Ter Keurs H.E. Fluorescent properties of rat cardiac trabeculae microinjected with fura-2 salt. Am J Physiol 264 (1993) H1098-H1110
7. von Anrep G. On the part played by the suprarenals in the normal vascular reactions on the body. J Physiol 45 (1912) 307-317
8. Alvarez B.V., Perez N.G., Ennis I.L., Camilion de Hurtado M.C., and Cingolani H.E. Mechanisms underlying the increase in force and Ca(2+) transient that follow stretch of cardiac muscle: a possible explanation of the Anrep effect. Circ Res 85 (1999) 716-722
9. Schaefer J., Deppert W., Lie R.K., Lohff B., and Noble M.I.M. Historical note on the translation of H.P. Bowditch's paper 'Uber die Eigenthümlichketn der Reizbarkeit, welche die Muskelfasern des Herzens zeigen' (On the peculiarities of excitability which the fibres of cardiac muscle show). In: Noble M.I.M., and Seed W.A. (Eds). The interval-force relationship of the heart: Bowditch revised (2006), Cambridge University Press, Cambridge 31-39
10. Lakatta E.G. Beyond Bowditch: the convergence of cardiac chronotropy and inotropy. Cell Calcium 35 (2004) 629-642
11. O'Laughlin M.P., and Fisher D.J. Mechanisms of congestive heart failure. In: Garson A., Bricker J.T., and McNamara D.G. (Eds). The science and practice of pediatric cardiology (1990), Williams & Wilkins, Baltimore 244-249
12. Kay J.D., Colan S.D., and Graham Jr. T.P. Congestive heart failure in pediatric patients. Am Heart J 142 (2001) 923-928
13. Krayenbuehl H.P., Hess O.M., Schneider J., and Turina M. Physiologic or pathologic hypertrophy. Eur Heart J 4 Suppl A (1983) 29-34
14. Katz A.M. The cardiomyopathy of overload: a hypothesis. J Cardiovasc Pharmacol 18 Suppl 2 (1991) S68-S71
15. Zak R. Cardiac hypertrophy: biochemical and cellular relationships. Hosp Pract (Off Ed) 18 (1983) 85-97
16. Colucci WS, Braunwald E. Pathophysiology of heart failure. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine, 5th ed. 1997. p. 394-420.
17. Weber K.T., Janicki J.S., Shroff S.G., Pick R., Chen R.M., and Bashey R.I. Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res 62 (1988) 757-765
18. Guyton AC, Hall JE, editors. Nervous regulation of the circulation, and rapid control of arterial pressure. In: Textbook of medical physiology, 10th ed., 2000.
19. Cohn J.N., Levine T.B., Olivari M.T., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311 (1984) 819-823
20. Podrid P.J., Fuchs T., and Candinas R. Role of the sympathetic nervous system in the genesis of ventricular arrhythmia. Circulation 82 Suppl (1990) I103-I113
21. Hafizi S., Wharton J., Morgan K., et al. Expression of functional angiotensin-converting enzyme and AT1 receptors in cultured human cardiac fibroblasts. Circulation 98 (1998) 2553-2559
22. Mazzolai L., Nussberger J., Aubert J.F., et al. Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension 31 (1998) 1324-1330
23. Buchhorn R. Neurohormonal and immunologic aspects of pediatric heart failure. In: Shaddy R.E., and Wernovsky G. (Eds). Pediatric heart failure. 1st ed (2005), Taylor & Francis, London 105-136
24. Huhta J.C., Sante-Korang A., Serrano M., and Gudur S. The ontogeny of biochemical markers of cardiac dysfunction. Curr Opin Pediatr 17 (2005) 563-567
25. Takahashi N., Calderone A., Izzo Jr. N.J., Maki T.M., Marsh J.D., and Colucci W.S. Hypertrophic stimuli induce transforming growth factor-beta 1 expression in rat ventricular myocytes. J Clin Invest 94 (1994) 1470-1476
26. Kluger J., Cody R.J., and Laragh J.H. The contributions of sympathetic tone and the renin-angiotensin system to severe chronic congestive heart failure: response to specific inhibitors (prazosin and captopril). Am J Cardiol 49 (1982) 1667-1674
27. Dzau V.J. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 153 (1993) 937-942
28. Horio T. Pathophysiological role of cytokines in heart failure. Nippon Rinsho 64 (2006) 843-847
29. Levine B., Kalman J., Mayer L., Fillit H.M., and Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990) 236-241
30. Sihvola R.K., Koskinen P.K., Pulkkinen V.P., Tikkanen J.M., and Lemstrom K.B. Inhibition of tumor necrosis factor-alpha attenuates myocardial remodeling in rat cardiac allografts. J Heart Lung Transplant 25 (2006) 569-578
31. Mann D.L., McMurray J.J., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
32. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., and Willerson J.T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 (2003) 3133-3140
33. Teitel D.F. Developmental aspects of cardiac performance. In: Shaddy R.E., and Wernovsky G. (Eds). Pediatric heart failure. 1st ed (2005), Taylor & Francis, London 31-63
34. Liu W., Yasui K., Opthof T., et al. Developmental changes of Ca(2+) handling in mouse ventricular cells from early embryo to adulthood. Life Sci 71 (2002) 1279-1292
35. Chin T.K., Christiansen G.A., Caldwell J.G., and Thorburn J. Contribution of the sodium-calcium exchanger to contractions in immature rabbit ventricular myocytes. Pediatr Res 41 (1997) 480-485
36. Foster E., and Lease K.E. New untwist on diastole: what goes around comes back. Circulation 113 (2006) 2477-2479
37. Notomi Y., Srinath G., Shiota T., et al. Maturational and adaptive modulation of left ventricular torsional biomechanics: Doppler tissue imaging observation from infancy to adulthood. Circulation 113 (2006) 2534-2541
38. O'Connor C.M., Gattis W.A., and Swedberg K. Current and novel pharmacologic approaches in advanced heart failure. Am Heart J 135 (1998) S249-S263
39. Gheorghiade M., Benatar D., Konstam M.A., Stoukides C.A., and Bonow R.O. Pharmacotherapy for systolic dysfunction: a review of randomized clinical trials. Am J Cardiol 80 (1997) 14H-27H
40. Hunt S.A. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 (2005) e1-e82
41. Cohn J.N. The management of chronic heart failure. N Engl J Med 335 (1996) 490-498
42. Iyengar S., and Abraham W.T. Diuretic resistance in heart failure. Curr Heart Fail Rep 3 (2006) 41-45
43. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
44. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
45. Zannad F., Alla F., Dousset B., Perez A., and Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Rales Investigators. Circulation 102 (2000) 2700-2706
46. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 325 (1991) 293-302
47. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316 (1987) 1429-1435
48. Shaddy R.E. Beta-adrenergic blockers in the treatment of pediatric heart failure. Prog Pediatr Cardiol 12 (2000) 113-118
49. Bruns L.A., and Canter C.E. Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure?. Paediatr Drugs 4 (2002) 771-778
50. Cleland J.G., Coletta A.P., Nikitin N.P., and Clark A.L. Clinical trials update from the American College of Cardiology: darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND. Eur J Heart Fail 8 (2006) 326-329
51. Giardini A., Formigari R., Bronzetti G., et al. Modulation of neurohormonal activity after treatment of children in heart failure with carvedilol. Cardiol Young 13 (2003) 333-336
52. Gheorghiade M., Adams Jr. K.F., and Colucci W.S. Digoxin in the management of cardiovascular disorders. Circulation 109 (2004) 2959-2964
53. Gheorghiade M., and Ferguson D. Digoxin. A neurohormonal modulator in heart failure?. Circulation 84 (1991) 2181-2186
54. Ferguson D.W., Berg W.J., Sanders J.S., Roach P.J., Kempf J.S., and Kienzle M.G. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation 80 (1989) 65-77
55. Ross R.D. Medical management of chronic heart failure in children. Am J Cardiovasc Drugs 1 (2001) 37-44
56. Hougen T.J. Digitalis use in children: an uncertain future. Prog Pediatr Cardiol 4 12 (2000) 37-43
57. Hood Jr. W.B., Dans A.L., Guyatt G.H., Jaeschke R., and McMurray J.J. Digitalis for treatment of congestive heart failure in patients in sinus rhythm. Cochrane Database Syst Rev 2 (2004) CD0 02901
58. Emerman C.L. Safety and efficacy of nesiritide for the treatment of decompensated heart failure. Rev Cardiovasc Med 3 Suppl 4 (2002) S28-S34
59. Mahle W.T., Cuadrado A.R., Kirshbom P.M., Kanter K.R., and Simsic J.M. Nesiritide in infants and children with congestive heart failure. Pediatr Crit Care Med 6 (2005) 543-546
60. Sehra R., and Underwood K. Nesiritide use for critically ill children awaiting cardiac transplantation. Pediatr Cardiol 27 (2006) 47-50
61. Topol E.J. Nesiritide-not verified. N Engl J Med 353 (2005) 113-116
62. Strey CH, Young JM, Lainchbury JH, et al. Short-term statin therapy improves endothelial function and neurohormonal imbalance in normocholesteraemic patients with non-ischaemic heart failure. Heart 2006.
63. Node K., Fujita M., Kitakaze M., Hori M., and Liao J.K. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839-843
64. Fukuta H., Sane D.C., Brucks S., and Little W.C. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 112 (2005) 357-363